|
|
Recent Articles
-
Nike’s Revenue to Face Pressure During First Half of Fiscal 2025
Mar 22, 2024
-
Image: Nike’s shares have faced considerable pressure from the beginning of 2022, and its outlook for the first half of fiscal 2025 wasn’t great.
We’re huge fans of Nike’s consecutive dividend growth track record, but uncertainty regarding the future pace of sales growth in China, growing competition from the likes of Lululemon and Vuori, and macro-driven weakness expected in the first half of fiscal 2025 leave us on the sidelines for now. Shares yield ~1.5% at the time of this writing.
-
Understanding Stock Splits
Mar 22, 2024
-
Let’s dig into how stock splits impact valuation.
-
Dividend Increases/Decreases for the Week of March 22
Mar 22, 2024
-
Let's take a look at firms raising/lowering their dividends this week.
-
Pfizer 6% Dividend Yield Speaks of Considerable Risk, Free Cash Flow Coming Up Short
Mar 21, 2024
-
Image: Pfizer’s shares have been under considerable pressure the past few years.
Though we are positive on Pfizer’s turnaround, its Dividend Cushion ratio of 0.3 is not to be taken lightly (any ratio below 1 indicates heightened risk of a dividend cut). Income-oriented investors seeking a turnaround story may be interested in Pfizer, but we’re staying on the sidelines. We’ll continue to monitor developments at the pharma giant, especially as patents on several of its major drugs approach expiration. Shares yield ~6% at the time of this writing.
|
